# Perfusion Medical, Inc.

Canonical: https://abierto.us/vendors/perfusion-medical-inc-xedjgxp1k889

- UEI: XEDJGXP1K889
- CAGE: 8MYE9
- Location: Herndon, VA
- Awards in window: 5 (14 transactions), $5,208,982 obligated, February 8, 2024 to April 3, 2026

## Awarding agencies

- Department of the Air Force: 3 awards, $3,709,209
- Defense Health Agency: 2 awards, $1,499,773

## Industries

- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology): $5,208,982

## Competition

- Full and Open Competition After Exclusion of Sources: 5 awards

## Largest awards

- FA864924P0531 (purchase order): $1,799,970, FA8649 USAF SBIR STTR Cntrctng AFRL. Human Clinical Trial for Safety of PM-208 Anti-Shock Drug. https://www.usaspending.gov/award/CONT_AWD_FA864924P0531_9700_-NONE-_-NONE-/
- FA864924P0552 (purchase order): $1,799,322, FA8649 USAF SBIR STTR Cntrctng AFRL. Research and Development of Optimal Dosing and Formulation of PM-208 (Peg-20k/8k) for Af Field Use. https://www.usaspending.gov/award/CONT_AWD_FA864924P0552_9700_-NONE-_-NONE-/
- HT942726CE025 (definitive contract): $1,499,773, Defense Health Agency. Ind-Enabling Studies of PM-208: a Novel Pre-Hospital Anti-Shock Therapeutic. https://www.usaspending.gov/award/CONT_AWD_HT942726CE025_9700_-NONE-_-NONE-/
- FA864924P0833 (purchase order): $109,917, FA8649 USAF SBIR STTR Cntrctng AFRL. Polyethylene Glycol-20k/8k (Peg-20k/8k): a Patented Intravenous Solution in Uncontrolled Hemorrhage. https://www.usaspending.gov/award/CONT_AWD_FA864924P0833_9700_-NONE-_-NONE-/
- HT942523C0065 (definitive contract): $0, Army Med Res Acq Activity. DHA SBIR Direct to Phase II - II Proposal H2D-0122: "ind-Enabling Studies of PM-208: a Novel Prehospital Anti-Shock Therapeutic". https://www.usaspending.gov/award/CONT_AWD_HT942523C0065_9700_-NONE-_-NONE-/

---
Source: USAspending.gov award data, keyed by UEI. Obligations in the window only. Cite https://abierto.us/vendors/perfusion-medical-inc-xedjgxp1k889.